Search
Travere Therapeutics Inc
TVTXAdd to Watchlist
56.920USD
+0.580+1.03%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
5.26BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Travere Therapeutics Inc is 8.67, ranking 75 out of 387 in the Biotechnology & Medical Research industry. The average price target is 41.00, with a high of 49.00 and a low of 31.00.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
58.769
Target Price
+4.31%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Travere Therapeutics Inc
TVTX
15
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Travere Therapeutics Inc's expected revenue for the next quarter?
Travere Therapeutics Inc's expected revenue is 160.66M.
What is Travere Therapeutics Inc's price target?
Analysts forecast that Travere Therapeutics Inc's price target is USD 41.00, with the highest forecast at USD 49.00 and the lowest forecast at USD 31.00.
How have Travere Therapeutics IncTVTX's recent earnings per share performed?
The market expectation was USD -0.40, while Travere Therapeutics IncTVTX's earnings per share (EPS) for the previous quarter was USD 0.03. EPS for the next quarter is expected at USD -0.10.
What is the analyst rating for Travere Therapeutics Inc?
Based on the ratings of Travere Therapeutics Inc's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.